Currently, IBD therapy is directed toward dampening the inflammatory response in the gastrointestinal tract to alleviate symptoms and involves the use of immunomodulators, anti-tumor necrosis factor-alpha (TNF-α) antibodies, 5-aminosalicylic acid agents, and antimicrobials (Baumgart and Sandborn, 2012; Cheifetz et al., 2017). The gene discussed is TNF; the disease is inflammatory bowel disease.